12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

ImmuNext, J&J deal

ImmuNext granted Johnson & Johnson's Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize products that antagonize the V-region immunoglobulin-containing suppressor of T cell activation (VISTA). J&J plans...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >